vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Waterstone Financial, Inc. (WSBF). Click either name above to swap in a different company.
Waterstone Financial, Inc. is the larger business by last-quarter revenue ($37.2M vs $18.7M, roughly 2.0× CytomX Therapeutics, Inc.). On growth, Waterstone Financial, Inc. posted the faster year-over-year revenue change (16.7% vs -25.7%). Waterstone Financial, Inc. produced more free cash flow last quarter ($23.0M vs $-15.8M). Over the past eight quarters, Waterstone Financial, Inc.'s revenue compounded faster (7.1% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Waterstone Financial, Inc. is a U.S. bank holding company headquartered in Wisconsin. It offers retail and commercial banking services, residential mortgages, and wealth management solutions, primarily serving consumers and small to medium-sized businesses across the U.S. Midwest region.
CTMX vs WSBF — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $37.2M |
| Net Profit | $-154.0K | — |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 27.0% |
| Net Margin | -0.8% | — |
| Revenue YoY | -25.7% | 16.7% |
| Net Profit YoY | 97.6% | — |
| EPS (diluted) | — | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $37.2M | ||
| Q3 25 | — | $37.0M | ||
| Q2 25 | $18.7M | $38.0M | ||
| Q1 25 | $50.9M | $29.7M | ||
| Q4 24 | $38.1M | $31.8M | ||
| Q3 24 | $33.4M | $34.1M | ||
| Q2 24 | $25.1M | $37.2M | ||
| Q1 24 | $41.5M | $32.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | $7.9M | ||
| Q2 25 | $-154.0K | $7.7M | ||
| Q1 25 | $23.5M | $3.0M | ||
| Q4 24 | $18.9M | — | ||
| Q3 24 | $5.7M | $4.7M | ||
| Q2 24 | $-6.5M | $5.7M | ||
| Q1 24 | $13.8M | $3.0M |
| Q4 25 | — | 27.0% | ||
| Q3 25 | — | 26.6% | ||
| Q2 25 | -6.9% | 25.4% | ||
| Q1 25 | 44.4% | 13.1% | ||
| Q4 24 | 46.4% | 19.5% | ||
| Q3 24 | 12.3% | 17.3% | ||
| Q2 24 | -33.7% | 19.2% | ||
| Q1 24 | 28.1% | 14.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | 21.4% | ||
| Q2 25 | -0.8% | 20.3% | ||
| Q1 25 | 46.2% | 10.2% | ||
| Q4 24 | 49.6% | — | ||
| Q3 24 | 17.2% | 13.9% | ||
| Q2 24 | -26.0% | 15.4% | ||
| Q1 24 | 33.3% | 9.4% |
| Q4 25 | — | $0.43 | ||
| Q3 25 | — | $0.45 | ||
| Q2 25 | — | $0.43 | ||
| Q1 25 | — | $0.17 | ||
| Q4 24 | — | $0.28 | ||
| Q3 24 | — | $0.26 | ||
| Q2 24 | — | $0.31 | ||
| Q1 24 | — | $0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | — |
| Total DebtLower is stronger | — | $412.3M |
| Stockholders' EquityBook value | $119.9M | $349.4M |
| Total Assets | $175.1M | $2.3B |
| Debt / EquityLower = less leverage | — | 1.18× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $36.2M | — |
| Q4 25 | — | $412.3M | ||
| Q3 25 | — | $469.1M | ||
| Q2 25 | — | $465.7M | ||
| Q1 25 | — | $395.9M | ||
| Q4 24 | — | $446.5M | ||
| Q3 24 | — | $560.1M | ||
| Q2 24 | — | $660.8M | ||
| Q1 24 | — | $634.2M |
| Q4 25 | — | $349.4M | ||
| Q3 25 | — | $345.5M | ||
| Q2 25 | $119.9M | $341.5M | ||
| Q1 25 | $25.0M | $341.4M | ||
| Q4 24 | $-456.0K | $339.1M | ||
| Q3 24 | $-23.5M | $342.0M | ||
| Q2 24 | $-31.2M | $334.9M | ||
| Q1 24 | $-31.7M | $338.0M |
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $2.3B | ||
| Q2 25 | $175.1M | $2.3B | ||
| Q1 25 | $98.5M | $2.2B | ||
| Q4 24 | $120.5M | $2.2B | ||
| Q3 24 | $139.0M | $2.2B | ||
| Q2 24 | $159.2M | $2.3B | ||
| Q1 24 | $184.7M | $2.2B |
| Q4 25 | — | 1.18× | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | 1.36× | ||
| Q1 25 | — | 1.16× | ||
| Q4 24 | — | 1.32× | ||
| Q3 24 | — | 1.64× | ||
| Q2 24 | — | 1.97× | ||
| Q1 24 | — | 1.88× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $24.2M |
| Free Cash FlowOCF − Capex | $-15.8M | $23.0M |
| FCF MarginFCF / Revenue | -84.6% | 61.9% |
| Capex IntensityCapex / Revenue | 0.1% | 3.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $43.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $24.2M | ||
| Q3 25 | — | $32.7M | ||
| Q2 25 | $-15.8M | $-38.4M | ||
| Q1 25 | $-21.0M | $26.7M | ||
| Q4 24 | $-19.9M | $48.1M | ||
| Q3 24 | $-20.7M | $74.1M | ||
| Q2 24 | $-19.5M | $-39.5M | ||
| Q1 24 | $-26.0M | $-9.9M |
| Q4 25 | — | $23.0M | ||
| Q3 25 | — | $32.4M | ||
| Q2 25 | $-15.8M | $-38.5M | ||
| Q1 25 | $-21.2M | $26.5M | ||
| Q4 24 | $-20.0M | $47.0M | ||
| Q3 24 | $-20.7M | $73.9M | ||
| Q2 24 | $-19.6M | $-39.7M | ||
| Q1 24 | $-26.2M | $-10.3M |
| Q4 25 | — | 61.9% | ||
| Q3 25 | — | 87.5% | ||
| Q2 25 | -84.6% | -101.2% | ||
| Q1 25 | -41.6% | 89.2% | ||
| Q4 24 | -52.5% | 147.5% | ||
| Q3 24 | -62.1% | 216.9% | ||
| Q2 24 | -78.2% | -106.7% | ||
| Q1 24 | -63.1% | -31.9% |
| Q4 25 | — | 3.1% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | 0.1% | 0.2% | ||
| Q1 25 | 0.2% | 0.9% | ||
| Q4 24 | 0.2% | 3.5% | ||
| Q3 24 | 0.1% | 0.6% | ||
| Q2 24 | 0.4% | 0.4% | ||
| Q1 24 | 0.3% | 1.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | 4.13× | ||
| Q2 25 | — | -4.98× | ||
| Q1 25 | -0.89× | 8.81× | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | 15.67× | ||
| Q2 24 | — | -6.92× | ||
| Q1 24 | -1.89× | -3.27× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
WSBF
Segment breakdown not available.
